A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
Price : $35 *
At a glance
- Drugs Mivavotinib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda; Takeda Oncology
- 07 Feb 2019 Planned number of patients changed from 38 to 47.
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.
- 11 Aug 2017 Planned initiation date changed from 2 Aug 2017 to 31 Aug 2017.